Plug­ging in the last piece to its gene ther­a­py puz­zle, AskBio ac­quires Scot­tish syn­thet­ic pro­mot­er com­pa­ny

AskBio is putting some of their re­cent $235 mil­lion raise to use, adding an­oth­er key piece to its ex­pan­sive gene ther­a­py toolk­it with the ac­qui­si­tion of Ed­in­burgh, Scot­land-based Syn­promics.

To be op­er­at­ed as a whol­ly-owned sub­sidiary at arms’-length — in fact, all the way across the At­lantic from AskBio’s home base in Re­search Tri­an­gle Park, NC — Syn­promics brings a gene con­trol syn­thet­ic pro­mot­er tech­nol­o­gy to the ta­ble. These are DNA se­quences that play a cru­cial role in the tran­scrip­tion of genes, specif­i­cal­ly those that drug de­vel­op­ers want to reg­u­late in the con­text of cell and gene ther­a­py.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER